Biotech & Pharma
Business Development

We have deep experience on both the buy and sell-side, and work with our clients to ensure that partnership, licensing and investment decisions are taken with confidence, along with clear alignment between transaction price and asset value. 

Scroll down to learn more

Biotech & Pharma Business Development Services

In-Licensing & Asset Scouting

We help companies and investors find new opportunities, working alongside a client’s team to maximize their effectiveness.

Due
Diligence

We work closely with our clients, using the breadth and depth of our consulting talent to undertake all aspects of due diligence.

Pharma &
Biotech Valuations

Our expert teams develop in-depth valuation models for our clients, helping inform strategic decision-making and investments.

Out-Licensing, Partnering
& Deal-making

We use a tailored approach to support in- and out-licensing needs, advising clients on both sides of the table.



About our business development capabilities

Alacrita's technical and scientific expertise allows it to deeply understand the science behind biotech and pharmaceutical assets - a core advantage in all business development work we do. Whether it’s in the ability to recognize potential assets when scouting, in developing the right assumptions for a valuation model, or with delivering due diligence that provides a complete and accurate assessment, knowing the science makes us more effective. 

Our consultants typically average 20-30 years of industry experience and bring significant first-hand knowledge to every project. Our core team works hand in hand with our Expert Network, which contains over 75 expert business development consultants, and more than 250 high-caliber consultants in total. Having this substantial resource at our fingertips allows us to provide precisely relevant expertise tailored to the specifics of each project, across a full range of product modalities and disease areas.


 

  • Autoimmune/Immunology
  • Cardiovascular
  • Central Nervous System
  • Congenital Disorders
  • Dermatology/Aesthetics
  • Digestive/GI
  • Ear
  • Endocrine and Metabolic
  • Fibrosis
  • Genitourinary Diseases
  • Haematology
  • Infectious Disease
  • Inflammation/Pain
  • Injuries and Trauma
  • Musculoskeletal
  • Non-medical
  • Oncology
  • Ophthalmology
  • Orphan Diseases
  • Respiratory
  • Urology (non-onc)
  • Women’s Health


Explore our pharma & biotech business development services

Contact Us

Reach out today for more information on our pharma business development services.

Biotech & Pharma Business Development Case Studies

Preclinical & clinical asset pipeline valuation

Challenge: A young biotech company with a portfolio of clinical and pre-clinical stage bispecific antibodies (BsAb) to treat various cancers was in the process of completing a Series A...

Presenting technology & clinical programs at ASH & SABCS

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its...

Asset scouting for in-licensing opportunities in fibrosis

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional...

Distressed company analysis for asset scouting

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company...

Scouting in-licensing opportunities for a mid-size pharma company

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing...

Valuation of a repurposed, male-fertility drug using Monte Carlo

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal...